[Inverse psoriasis].
Weisenseel P, Reich K.
Hautarzt. 2015 Jun;66(6):408-12. doi: 10.1007/s00105-015-3628-7.
Treatments for inverse psoriasis: a systematic review.
Reynolds KA, Pithadia DJ, Lee EB, Wu JJ.
J Dermatolog Treat. 2020 Dec;31(8):786-793. doi: 10.1080/09546634.2019.1620912. Epub 2019 May 31.
Inverse psoriasis.
Zampetti A, Tiberi S.
Clin Med (Lond). 2015 Jun;15(3):311. doi: 10.7861/clinmedicine.15-3-311.
Histopathologic features of inverse psoriasis.
Knabel M, Mudaliar K.
J Cutan Pathol. 2022 Mar;49(3):246-251. doi: 10.1111/cup.14142. Epub 2021 Oct 19.
Psoriasis: Recognition and Management Strategies.
Garner KK, Hoy KDS, Carpenter AM.
Am Fam Physician. 2023 Dec;108(6):562-573.
Hydroxychloroquine-induced inverse psoriasis.
Ullah A, Zeb H, Khakwani Z, Murphy FT.
BMJ Case Rep. 2019 Feb 28;12(2):e224619. doi: 10.1136/bcr-2018-224619.
Association Between Psoriasis and Nonalcoholic Fatty Liver Disease Among Outpatient US Adults.
Ruan Z, Lu T, Chen Y, Yuan M, Yu H, Liu R, Xie X.
JAMA Dermatol. 2022 Jul 1;158(7):745-753. doi: 10.1001/jamadermatol.2022.1609.
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C, Naldi L, Kinberger M, Afach S, Le Cleach L.
Cochrane Database Syst Rev. 2023 Jul 12;7(7):CD011535. doi: 10.1002/14651858.CD011535.pub6.
Psoriasis.
Weigle N, McBane S.
Am Fam Physician. 2013 May 1;87(9):626-33.
Psoriasis Risk With Immune Checkpoint Inhibitors.
To SY, Lee CH, Chen YH, Hsu CL, Yang HW, Jiang YS, Wen YL, Chen IW, Kao LT.
JAMA Dermatol. 2025 Jan 1;161(1):31-38. doi: 10.1001/jamadermatol.2024.4129.
